A Prospective Phase II Trial Of Novottf-100A With Bevacizumab (Avastin) In Patients With Recurrent Glioblastoma
Posted Date: Mar 28, 2018
- Investigator: Rekha Chaudhary
- Specialties: Hematology/Oncology, Oncology, Neurosurgery, Cancer, Neurology
- Type of Study: Drug
The purpose of this study is to determine the efficacy of the combination of Bevacizumab and NovoTTF-100A in Bevacizumab naïve (meaning you have never received bevacizumab before) patients with recurrent GBM as measured by 6-month progression free survival.
To Be Eligible For This Study, Patients Must Have Been Diagnosed With A Brain Tumor Called Glioblastoma Or Other Grade Iv Malignant Glioma (I.E. Gliosarcoma, Small Cell Glioblastoma, Etc).
Cancer, Glioma, Brain Tumor, Cae3313, Brain
For More Information:
Uc Cancer Institute